Completion of Sale

RNS Number : 5204P

Venn Life Sciences Holdings PLC

18 November 2016

 

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Completion of Sale

Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that further to the announcements on 4 October 2016 and 27 October 2016 it has completed the sale of its shareholding in Innovenn UK Limited to Integumen Limited and that Integumen Limited is currently going through an IPO process. Venn is receiving ordinary shares of £1.00 each in Integumen as consideration.

Enquiries:

Venn Life Sciences Holdings Plc		www.vennlifesciences.com
Tony Richardson, Chief Executive Officer		Tel: [phone]
Jonathan Hartshorn, Chief Financial Officer		Tel: [phone]
Aoife O Farrell, Marketing Manager		Tel: [phone]
Davy (Nominated Adviser, ESM Adviser and Joint Broker)		Tel: [phone]
Fergal Meegan / Matthew DeVere White (Corporate Finance)
Paul Burke (Corporate Broking)
Hybridan LLP (Joint-Broker)
Claire Louise Noyce		Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or           [e-mail]
Paul McManus		Mob: [phone]
Lianne Cawthorne		Mob: [phone]

About Venn Life Sciences: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases.

For more information about the Company, please visit: www.vennlifesciences.com

 

END

 

 

DISDDBDBUUBBGLR